{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:26:21Z","timestamp":1767713181481,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-023-02796-x","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T20:19:17Z","timestamp":1688761157000},"page":"3943-3952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Application of topical 2% cyclosporine A in inflammatory ocular surface diseases"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6848-203X","authenticated-orcid":false,"given":"Leyla","family":"Asena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Dursun Alt\u0131n\u00f6rs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"issue":"5","key":"2796_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3109\/09273948.2010.498657","volume":"18","author":"CA Utine","year":"2010","unstructured":"Utine CA, Stern M, Akpek EK (2010) Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm 18(5):352\u2013361. https:\/\/doi.org\/10.3109\/09273948.2010.498657","journal-title":"Ocul Immunol Inflamm"},{"key":"2796_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.survophthal.2009.02.002","volume":"54","author":"E Donnenfeld","year":"2009","unstructured":"Donnenfeld E, Pflugfelder SC (2009) Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 54:321\u2013338","journal-title":"Surv Ophthalmol"},{"key":"2796_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/14656566.2018.1479742","volume":"19","author":"KG Boboridis","year":"2018","unstructured":"Boboridis KG, Konstas AGP (2018) Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. Expert Opin Pharmacother 19:1027\u20131039","journal-title":"Expert Opin Pharmacother"},{"key":"2796_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5301\/ejo.5000779","volume":"26","author":"A Leonardi","year":"2016","unstructured":"Leonardi A, Van Setten G, Amrane M, Amrane M, Ismail D, Garrigue JS et al (2016) Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 26:287\u2013296","journal-title":"Eur J Ophthalmol"},{"key":"2796_CR5","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1097\/ICO.0b013e3181e456f0","volume":"29","author":"JB Malta","year":"2010","unstructured":"Malta JB, Soong HK, Shtein RM, Musch DC, Rhoades W, Sugar A et al (2010) Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea 29:1392\u20136","journal-title":"Cornea"},{"key":"2796_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ajo.2005.11.042","volume":"141","author":"SN Rao","year":"2006","unstructured":"Rao SN (2006) Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol 141:771\u20132","journal-title":"Am J Ophthalmol"},{"key":"2796_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/01.iio.0000212135.77675.6a","volume":"46","author":"GN Foulks","year":"2006","unstructured":"Foulks GN (2006) Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin 46:105\u2013122","journal-title":"Int Ophthalmol Clin"},{"key":"2796_CR8","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1136\/bjophthalmol-2013-304072","volume":"98","author":"M Sacchetti","year":"2014","unstructured":"Sacchetti M, Mantelli F, Lambiase A (2014) Systematic review of randomized clinical trials on topical cyclosporine A for the treatment of dry eye disease. Br J Ophthalmol 98:1016\u20131022","journal-title":"Br J Ophthalmol"},{"key":"2796_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5301\/ejo.5000952","volume":"27","author":"C Baudouin","year":"2017","unstructured":"Baudouin C, Figueiredo FC, Messmer EM, Ismail D, Amrane M, Garrigue JS et al (2017) A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol 27:520\u2013530","journal-title":"Eur J Ophthalmol"},{"key":"2796_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ajo.2005.08.035","volume":"141","author":"S Doan","year":"2006","unstructured":"Doan S, Gabison E, Gatinel D, Duong MH, Abitbol O, Hoang-Xuan T (2006) Topical cyclosporine A in severe steroid-dependent childhood phlyctenular keratoconjunctivitis. Am J Ophthalmol 141:62\u201366","journal-title":"Am J Ophthalmol"},{"key":"2796_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s004170050257","volume":"237","author":"A Heiligenhaus","year":"1999","unstructured":"Heiligenhaus A, Steuhl KP (1999) Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol 237:435\u2013438","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2796_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s004170050204","volume":"237","author":"T Reinhard","year":"1999","unstructured":"Reinhard T, Sundmacher R (1999) Topical cyclosporin A in Thygeson\u2019s superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol 237:109\u2013112","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2796_CR13","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0161-6420(98)99043-1","volume":"105","author":"M Hingorani","year":"1998","unstructured":"Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S (1998) A randomized, placebo-controlled trial of topical cyclosporin A in steroid dependent atopic keratoconjunctivitis. Ophthalmology 105:1715\u20131720","journal-title":"Ophthalmology"},{"key":"2796_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1081-1206(10)61958-8","volume":"89","author":"N Pucci","year":"2002","unstructured":"Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R et al (2002) Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 89:298\u2013303","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2796_CR15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/00003226-200403000-00014","volume":"23","author":"A Cetinkaya","year":"2004","unstructured":"Cetinkaya A, Akova YA, Dursun D, Pelit A (2004) Topical cyclosporine in the management of shield ulcers. Cornea 23:194\u2013200","journal-title":"Cornea"},{"issue":"8","key":"2796_CR16","first-page":"1087","volume":"106","author":"R Deshmukh","year":"2022","unstructured":"Deshmukh R, Ting DSJ, Elsahn A, Mohammed I, Said DG, Dua HS (2022) Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases. Br J Ophthalmol. 106(8):1087\u20131092","journal-title":"Br J Ophthalmol."},{"key":"2796_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ajo.2003.10.036","volume":"137","author":"SC Pflugfelder","year":"2004","unstructured":"Pflugfelder SC (2004) Antiinflammatory therapy for dry eye. Am J Ophthalmol 137:337\u2013342","journal-title":"Am J Ophthalmol"},{"key":"2796_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1517\/14740338.7.1.79","volume":"7","author":"S Kashani","year":"2008","unstructured":"Kashani S, Mearza AA (2008) Uses and safety profile of cyclosporin in ophthalmology. Expert Opin Drug Saf 7:79\u201389","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"2796_CR19","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1136\/bjophthalmol-2013-304728","volume":"98","author":"P Aragona","year":"2014","unstructured":"Aragona P (2014) Topical cyclosporine: are all indications justified? Br J Ophthalmol 98(8):1001\u20131002","journal-title":"Br J Ophthalmol"},{"key":"2796_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/01.ico.0000176611.88579.0a","volume":"25","author":"HD Perry","year":"2006","unstructured":"Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH (2006) Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 25:171\u2013175","journal-title":"Cornea"},{"key":"2796_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/jop.2006.22.47","volume":"22","author":"M Rubin","year":"2006","unstructured":"Rubin M, Rao SN (2006) Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther 22:47\u201353","journal-title":"J Ocul Pharmacol Ther"},{"key":"2796_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s12325-009-0037-2","volume":"26","author":"BA Schechter","year":"2009","unstructured":"Schechter BA, Katz RS, Friedman LS (2009) Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 26:651\u2013659","journal-title":"Adv Ther"},{"key":"2796_CR23","first-page":"Cd003262","volume":"3","author":"EJ van Zuuren","year":"2011","unstructured":"van Zuuren EJ, Kramer S, Carter B, Graber MA, Fedorowicz Z (2011) Interventions for rosacea. Cochrane Database Syst Rev 3:Cd003262","journal-title":"Cochrane Database Syst Rev"},{"key":"2796_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/ICU.0000000000000399","volume":"28","author":"ST Rousta","year":"2017","unstructured":"Rousta ST (2017) Pediatric blepharokeratoconjunctivitis: is there a \u201cright\u201d treatment? Curr Opin Ophthalmol 28:449\u2013453","journal-title":"Curr Opin Ophthalmol"},{"key":"2796_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/00006324-200306000-00007","volume":"80","author":"J Albietz","year":"2003","unstructured":"Albietz J, Sanfilippo P, Troutbeck R, Lenton LM (2003) Management of filamentary keratitis associated with aqueous-deficient dry eye. Optom Vis Sci 80:420\u2013430","journal-title":"Optom Vis Sci"},{"key":"2796_CR26","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","volume":"106","author":"P Marsh","year":"1999","unstructured":"Marsh P, Pflugfelder SC (1999) Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 106:811\u2013816","journal-title":"Ophthalmology"},{"key":"2796_CR27","first-page":"926","volume":"119","author":"A Grinbaum","year":"2001","unstructured":"Grinbaum A, Yassur I, Avni I (2001) The beneficial effect of diclofenac sodium in the treatment of filamentary keratitis. Arch Ophthalmol 119:926\u2013927","journal-title":"Arch Ophthalmol"},{"key":"2796_CR28","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/S0161-6420(03)00538-4","volume":"110","author":"HD Perry","year":"2003","unstructured":"Perry HD, Doshi-Carnevale S, Donnenfeld ED, Kornstein HS (2003) Topical cyclosporine A 0.5% as a possible new treatment for superior limbic keratoconjunctivitis. Ophthalmology 110:1578\u20131581","journal-title":"Ophthalmology"},{"key":"2796_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.survophthal.2015.04.001","volume":"60","author":"V Jhanji","year":"2015","unstructured":"Jhanji V, Chan TC, Li EY, Agarwal K, Vajpayee RB (2015) Adenoviral keratoconjunctivitis. Surv Ophthalmol 60:435\u2013443","journal-title":"Surv Ophthalmol"},{"key":"2796_CR30","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/ICO.0b013e3181c33034","volume":"29","author":"E Levinger","year":"2010","unstructured":"Levinger E, Slomovic A, Sansanayudh W, Bahar I, Slomovic AR (2010) Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea 29:638\u2013640","journal-title":"Cornea"},{"key":"2796_CR31","first-page":"12","volume":"18","author":"S Okumus","year":"2012","unstructured":"Okumus S, Coskun E, Tatar MG, Kaydu E, Yayuspayi R, Comez A et al (2012) Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis. BMC Ophthalmol 18:12\u201342","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"2796_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/eye.2017.4","volume":"31","author":"L Asena","year":"2017","unstructured":"Asena L, \u015e\u0131ngar \u00d6zdemir E, Burcu A, Ercan E, \u00c7olak M, Alt\u0131n\u00f6rs DD (2017) Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis. Eye 31(5):781\u2013787","journal-title":"Eye"},{"key":"2796_CR33","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.2147\/OPTH.S186543","volume":"12","author":"R Nuzzi","year":"2018","unstructured":"Nuzzi R, Tridico F (2018) How to minimize pterygium recurrence rates: clinical perspectives. Clin Ophthalmol 12:2347\u20132362","journal-title":"Clin Ophthalmol"},{"key":"2796_CR34","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2147\/OPTH.S19469","volume":"5","author":"E Turan-Vural","year":"2011","unstructured":"Turan-Vural E, Torun-Acar B, Kivanc SA, Acar S (2011) The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery. Clin Ophthalmol 5:881\u20135","journal-title":"Clin Ophthalmol"},{"issue":"Suppl 7","key":"2796_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5301\/ejo.5000004","volume":"22","author":"K \u00d6z\u00fclken","year":"2012","unstructured":"\u00d6z\u00fclken K, Ko\u00e7 M, Ayar O, Hasiripi H (2012) Topical cyclosporine A administration after pterygium surgery. Eur J Ophthalmol 22(Suppl 7):5\u201310","journal-title":"Eur J Ophthalmol"},{"key":"2796_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000268041","volume":"29","author":"K Gunduz","year":"1997","unstructured":"Gunduz K, Ozdemir O (1997) Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res 29:405\u2013408","journal-title":"Ophthalmic Res"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02796-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-023-02796-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02796-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T11:09:39Z","timestamp":1695640179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-023-02796-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2796"],"URL":"https:\/\/doi.org\/10.1007\/s10792-023-02796-x","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Institutional Review Board of Baskent University Faculty of Medicine and adhered to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained for the off-label use of topical 2% cyclosporin A from all individual participants included in this retrospective study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors affirm that participants provided informed consent for publication of the images in Figs. 1, 2, 3, 4 and 5.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}